Komori
Immuno-Biological Laboratories (4570) · RiskRestated

Risk of continued supply of sericulture technology, silkworm feed and other products

First written in FY2016. 3 of 4 entries say "Restated". Latest entry: FY2020.

4entries
5years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2016 – FY20202016: 120162017: 120172018: 020182019: 120192020: 12020
Same theme, other companies
Weakening supply base for sericulture technology, feed and mulberry leavesA theme 1 companies write about · 1 as a headwind · 0 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2020RestatedAnnual report

    「Higher costs for artificial feed are expected as a result of large-scale rearing, and we will continue efforts toward commercialization to secure mulberry leaves and reduce the cost of artificial feed.」

    Continues to address higher feed costs associated with the increase in the number of silkworms being raised, as well as the challenges of securing mulberry leaves and reducing artificial-feed costs.
  2. FY2019RestatedAnnual report

    「In addition, the number of genetically modified silkworms that must be raised to support the increasing number of research and development projects and the production of commercialized products, Laminin and Neosilk®-Human Collagen I, is expected to increase dramatically, resulting in higher costs for artificial feed due to large-scale rearing. To address this issue, we will continue efforts toward commercialization to secure mulberry leaves and reduce the cost of artificial feed.」

    Anticipates higher artificial-feed costs as the number of silkworms being raised increases and continues efforts to secure mulberry leaves and reduce feed costs.
  3. FY2017RestatedAnnual report

    「In addition, the number of genetically modified silkworms that must be raised to support the increasing number of research and development projects and the production of commercialized products, Laminin and Neosilk®-Human Collagen I, is expected to increase dramatically, resulting in higher costs for artificial feed due to large-scale rearing.」

    In addition to the risk of disruption to sericulture technology and feed supplies, identifies rising artificial-feed costs associated with the increase in the number of silkworms being raised as an issue.
  4. FY2016First statedAnnual report

    「The decline of Japan's sericulture industry and the aging of sericulture farmers have made succession increasingly difficult. In addition, uncertainty remains as to whether the supply infrastructure for materials required for sericulture, including silkworm feed, can remain stable over the long term under these conditions. If these supplies are disrupted, it may become difficult to continue the business.」

    Identifies the decline and aging of the sericulture industry and the supply infrastructure for feed and other materials as business continuity risks.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Immuno-Biological Laboratories yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Risk of continued supply of sericulture technology, silkworm feed and other products | Immuno-Biological Laboratories Co.,Ltd. (4570) | Komori